Fig. 3: Accumulation of NIL-IM-Lip in the tumour and LNs and the local hyperthermia effects.
a In vivo biodistribution imaging of the mice after injection of different formulations (i.v.). b Ex vivo imaging of the tumour, main organs and LNs at 48 h. c Average fluorescence intensities of the tumour, main organs and LNs at 48 h (n  =  3 biologically independent experiments). d Infrared thermal images of mice treated with NS, IR780, I-Lip and N-I-Lip under 1.0 W/cm2 laser irradiation (808 nm). e Temperature profiles of the mouse tumours after treatment with NS, IR780, I-Lip and N-I-Lip under 1.0 W/cm2 laser irradiation (808 nm) (n  =  3 biologically independent experiments). f Ex vivo imaging of LNs at 4, 8, and 12 h post-administration of Cy5.5-BSA, MMP2-non-sensitive and MMP2-sensitive. Cy.5.5-BSA was used to replace IL-15 for NIRF imaging (n  =  3 biologically independent experiments). g Total fluorescence intensities of the LNs at 4, 8, and 12 h post-administration of Cy5.5-BSA, MMP2-non-sensitive and MMP2-sensitive (n  =  3 biologically independent experiments). The data are shown as the mean ± SD (n  =  3 biologically independent experiments). Statistical significance was calculated by the one-way ANOVA analysis of variance with Tukey’s post hoc test. *P < 0.05, **P < 0.01, ***P < 0.001. Source data are provided as a Source Data file. I-Lip: IR780-Lip; N-I-Lip: NGR-IR780-Lip; Cy5.5-BSA: Cy5.5 labelled BSA; MMP2-non-sensitive: IL-15 modified on the NIL-IM-Lip by MMP2-non-sensitive peptide; MMP2 sensitive: IL-15 modified on the NIL-IM-Lip by MMP2 sensitive peptide.
